Jefferies reiterates Savara stock Buy rating on approval confidence
Jefferies has reiterated a Buy rating and $10.50 price target for Savara (NASDAQ:SVRA) due to high confidence in the regulatory approval of its Molbreevi treatment for autoimmune pulmonary alveolar proteinosis lung disease. The firm projects $500 million in U.S. peak sales and a potential EU approval by Q1 2027, with the stock currently trading at $5.05 after a 77% return over the past year. Regulatory hurdles have been addressed, and both the FDA and EMA are progressing with Molbreevi's applications without an advisory committee for the former.
How this was made
The 30-second read
Why it matters
Approval could lead to substantial stock appreciation and revenue growth, influencing investor sentiment and sector dynamics.
Market read
The news is highly relevant for biotech investors, especially those focusing on autoimmune disease treatments, with potential sector-wide implications.
What to watch
Potential competition from other autoimmune therapies; market acceptance risks; regulatory hurdles beyond approval.
Background
Savara is developing Molbreevi for autoimmune pulmonary alveolar proteinosis, with high confidence in regulatory approval based on recent progress.
Ticker impact
High relevance due to recent analyst upgrade and regulatory approval prospects.
Moderate to significant increase in stock price upon approval; potential rise of 20-30% over the next 6-12 months.
The analyst's confidence, high projected peak sales, and ongoing regulatory progress support a bullish outlook. The stock's current trading at $5.05, with a target of $10.50, indicates substantial upside if approval is achieved.
Market effects
Positive impact on biotech and pharmaceutical sectors, especially companies involved in autoimmune disease treatments.
Primarily U.S. and European markets, given the focus on FDA and EMA approvals.
Moderate; reflects broader interest in autoimmune therapies and biotech innovation.
Counterpoint
Regulatory approval is uncertain; approval delays or rejections could lead to significant stock declines.
Key entities
- CompanySavara Inc.
Biotech firm focused on therapies for rare pulmonary diseases.
- DrugMolbreevi
Investigational treatment for autoimmune pulmonary alveolar proteinosis.
- Regulatory AgencyFDA
U.S. Food and Drug Administration, overseeing drug approval.
- Regulatory AgencyEMA
European Medicines Agency, overseeing drug approval in the EU.


